STOCK TITAN

Jazz Pharmaceuticals plc - JAZZ STOCK NEWS

Welcome to our dedicated news page for Jazz Pharmaceuticals plc (Ticker: JAZZ), a resource for investors and traders seeking the latest updates and insights on Jazz Pharmaceuticals plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jazz Pharmaceuticals plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jazz Pharmaceuticals plc's position in the market.

Rhea-AI Summary
Jazz Pharmaceuticals plc (JAZZ) reported total revenues of $3.8 billion in 2023 with a 27% year-over-year increase driven by key growth drivers like Xywav, Epidiolex, and Rylaze. The company achieved its first $1 billion revenue quarter and anticipates double-digit revenue growth in 2024. Multiple late-stage pipeline catalysts are expected, with a 2024 revenue guidance of $4.0 to $4.2 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
earnings
-
Rhea-AI Summary
Jazz Pharmaceuticals plc appoints Patrick Kennedy, an experienced leader, to its Board of Directors, enhancing the company's focus on creating value for shareholders. Kennedy's financial and operating expertise aligns with Jazz's growth-oriented approach, aiming to transform patients' lives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
management
-
Rhea-AI Summary
Jazz Pharmaceuticals appoints Philip Johnson as Executive Vice President and CFO, bringing over 35 years of financial experience to the leadership team. Johnson will oversee various financial functions and drive growth and diversification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
management
Rhea-AI Summary
Jazz Pharmaceuticals plc (JAZZ) announces participation in upcoming investor conferences, including TD Cowen's 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Webcasts of the presentations will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
conferences
-
Rhea-AI Summary
Jazz Pharmaceuticals plc (JAZZ) will report its 2023 full year and fourth quarter financial results on February 28, 2024. A live audio webcast will be hosted to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
conferences earnings
-
Rhea-AI Summary
Jazz Pharmaceuticals' Chief People Officer discusses the innovative work model 'Jazz Remix' on the Future of HR Podcast, emphasizing flexible work environments and positive employee experiences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.94%
Tags
none
Rhea-AI Summary
Jazz Pharmaceuticals, founded in 2003, has evolved over the past 20 years to include treatment options for hematologic cancers and solid tumors, bringing over 11 therapeutics to market. Co-founder Bruce Cozadd prioritizes a people-first and mission-driven culture.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
none
-
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has signed a definitive agreement to acquire Redx Pharma plc's KRAS inhibitor program. The deal includes an upfront payment of $10 million to Redx, with the potential for up to $870 million in milestone payments. The collaboration aims to advance preclinical KRAS candidates through IND-enabling studies, with Jazz taking responsibility for clinical development, regulatory activities, manufacturing, and commercialization. Redx is also eligible for royalties on future net sales. The transaction expands Jazz's early-stage oncology pipeline and aims to address the high unmet need for innovative treatment options for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
acquisition
-
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announces Phase 2 trial results for investigational drug JZP150 in PTSD, with disappointing outcomes. The trial did not meet the primary or key secondary endpoints, leading the company to reconsider further development in PTSD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
clinical trial
Rhea-AI Summary
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) to webcast corporate presentation at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
conferences
Jazz Pharmaceuticals plc

Nasdaq:JAZZ

JAZZ Rankings

JAZZ Stock Data

7.48B
60.86M
2.64%
96.97%
3.69%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About JAZZ

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni